Related Experiment Video

Updated: Feb 5, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

416

[Research Progress of Targeted Therapy for BRAF Mutation 
in Advanced Non-small Cell Lung Cancer]

Xia Liu1, Diansheng Zhong1

  • 1Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China.

Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|September 3, 2018
PubMed

Insights

Targeted therapy offers new hope for advanced non-small cell lung cancer (NSCLC) patients with BRAF mutations. This review covers BRAF gene mutations and the latest targeted treatments for NSCLC.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Advanced non-small cell lung cancer (NSCLC) treatment relies on targeted therapies for specific driver gene mutations.
  • BRAF mutations are increasingly recognized as significant oncogenic drivers in NSCLC, alongside EGFR, ALK, and ROS1 alterations.
  • The BRAF V600E mutation is a prevalent subtype, representing a key therapeutic target.

Purpose of the Study:

  • To review the current understanding of BRAF gene mutations in NSCLC.
  • To summarize the advancements in targeted therapy for BRAF-mutated NSCLC.

Main Methods:

  • Literature review of studies on BRAF mutations and targeted therapies in NSCLC.
  • Analysis of clinical trial data and research publications.

Main Results:

  • BRAF mutations, particularly V600E, are actionable targets in a subset of NSCLC patients.
  • Targeted therapies show promise in improving outcomes for patients with BRAF-driven NSCLC.

Conclusions:

  • BRAF mutation status is crucial for guiding treatment decisions in advanced NSCLC.
  • Ongoing research continues to expand therapeutic options for BRAF-mutated NSCLC.
Keywords:
Lung neoplasmsTargeted therapyV-raf murine sar-coma viral oncogene homolog B1

More Related Videos

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.5K
Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs05:11

Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs

Published on: May 10, 2024

1.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.9K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.9K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.8K
Mutations01:39

Mutations

Overview
94.5K
Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.9K